Griffith D Parks Selected Research

cyclopropapyrroloindole

10/2019	Histone Deacetylase Inhibitors Enhance Cell Killing and Block Interferon-Beta Synthesis Elicited by Infection with an Oncolytic Parainfluenza Virus.
1/2018	Parainfluenza Virus Infection Sensitizes Cancer Cells to DNA-Damaging Agents: Implications for Oncolytic Virus Therapy.
4/2011	Activation of human macrophages by bacterial components relieves the restriction on replication of an interferon-inducing parainfluenza virus 5 (PIV5) P/V mutant.
2/2010	TLR3-dependent upregulation of RIG-I leads to enhanced cytokine production from cells infected with the parainfluenza virus SV5.
10/2008	A hyperfusogenic F protein enhances the oncolytic potency of a paramyxovirus simian virus 5 P/V mutant without compromising sensitivity to type I interferon.
7/2008	Virus growth and antibody responses following respiratory tract infection of ferrets and mice with WT and P/V mutants of the paramyxovirus Simian Virus 5.
1/2008	Paramyxovirus-induced shutoff of host and viral protein synthesis: role of the P and V proteins in limiting PKR activation.
10/2007	Role for the phosphoprotein P subunit of the paramyxovirus polymerase in limiting induction of host cell antiviral responses.
6/2006	Variants of the paramyxovirus Simian virus 5 with accelerated or delayed viral gene expression activate proinflammatory cytokine synthesis.
4/2006	A simian virus 5 (SV5) P/V mutant is less cytopathic than wild-type SV5 in human dendritic cells and is a more effective activator of dendritic cell maturation and function.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Griffith D Parks Research Topics

Disease

38	Infections 01/2023 - 02/2002
13	Paramyxoviridae Infections (Parainfluenza) 01/2023 - 06/2003
10	Neoplasms (Cancer) 01/2023 - 02/2002
7	Virus Diseases (Viral Diseases) 01/2023 - 09/2004
4	Vesicular Stomatitis 09/2022 - 06/2011
3	Neuroblastoma 01/2023 - 01/2018
3	Lung Neoplasms (Lung Cancer) 01/2023 - 10/2019
3	Human Influenza (Influenza) 01/2016 - 01/2014
2	Laryngeal Neoplasms (Laryngeal Cancer) 10/2019 - 01/2018
2	Coinfection 11/2003 - 06/2003
1	Zika Virus Infection 01/2022
1	COVID-19 01/2021
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 10/2019
1	Persistent Infection 01/2018
1	Whooping Cough (Pertussis) 07/2014
1	Carcinoma (Carcinomatosis) 04/2005

Drug/Important Bio-Agent (IBA)

13	cyclopropapyrroloindoleIBA 10/2019 - 10/2002
11	Complement System Proteins (Complement)IBA 01/2023 - 06/2008
11	Proteins (Proteins, Gene)FDA Link 04/2022 - 10/2002
7	Antiviral Agents (Antivirals)IBA 09/2022 - 12/2013
7	VaccinesIBA 06/2022 - 09/2010
5	CytokinesIBA 01/2023 - 04/2006
5	InterferonsIBA 01/2021 - 11/2003
4	Interferon-betaIBA 10/2019 - 10/2002
4	Interleukin-6 (Interleukin 6)IBA 09/2010 - 06/2006
3	DNA (Deoxyribonucleic Acid)IBA 01/2023 - 01/2018
2	AntigensIBA 01/2023 - 10/2011
2	CaspasesIBA 01/2023 - 01/2020
2	Interferon Type IIBA 04/2022 - 10/2008
2	Glycoproteins (Glycoprotein)IBA 01/2021 - 06/2011
2	Immunoglobulin G (IgG)IBA 02/2015 - 07/2008
2	Small Interfering RNA (siRNA)IBA 02/2010 - 09/2009
2	Interleukin-8 (Interleukin 8)IBA 06/2006 - 06/2003
2	Viral ProteinsIBA 04/2006 - 06/2005
1	MethyltransferasesIBA 01/2023
1	EnzymesIBA 01/2023
1	Azacitidine (5 Azacytidine)FDA Link 01/2023
1	N-methyl-valyl-amiclenomycin (BA 2)IBA 06/2022
1	Caspase 8 (Caspase-8)IBA 04/2022
1	Biomarkers (Surrogate Marker)IBA 01/2022
1	Interferon LambdaIBA 01/2021
1	Natural Killer Cell ReceptorsIBA 01/2021
1	scriptaidIBA 10/2019
1	Histone Deacetylases (Histone Deacetylase)IBA 10/2019
1	Histone Deacetylase InhibitorsIBA 10/2019
1	Double-Stranded RNA (RNA, Double Stranded)IBA 10/2019
1	Interferon Regulatory Factor-3 (Interferon Regulatory Factor 3)IBA 10/2019
1	Salivary Proteins and PeptidesIBA 07/2019
1	GoldIBA 07/2019
1	Membrane Glycoproteins (Membrane Glycoprotein)IBA 01/2018
1	Cisplatin (Platino)FDA LinkGeneric 01/2018
1	FlagellinIBA 07/2015
1	Immunoglobulin A (IgA)IBA 08/2014
1	AntibodiesIBA 07/2014
1	Chemokine ReceptorsIBA 11/2012
1	LuciferasesIBA 06/2011
1	Carrier Proteins (Binding Protein)IBA 02/2010
1	RNA-Binding Proteins (RNA-Binding Protein)IBA 09/2009
1	Tretinoin (Retinoic Acid)FDA LinkGeneric 09/2009
1	Interleukin-12 (IL 12)IBA 11/2008
1	Membrane Proteins (Integral Membrane Proteins)IBA 10/2008
1	Cysteine (L-Cysteine)FDA Link 10/2007
1	Viral RNAIBA 06/2006
1	Chemokine CCL5IBA 06/2006
1	Chemotactic FactorsIBA 06/2006
1	Caspase 3 (Caspase-3)IBA 04/2006
1	Viral AntigensIBA 09/2004
1	UbiquitinIBA 09/2004
1	Peptides (Polypeptides)IBA 09/2004
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 06/2003
1	ChemokinesIBA 06/2003
1	ProdrugsIBA 02/2002
1	Thymidine KinaseIBA 02/2002

Therapy/Procedure

6	Therapeutics 01/2023 - 07/2014
2	Oncolytic Virotherapy 01/2023 - 01/2018
1	Personal Protective Equipment 06/2022
1	Drug Therapy (Chemotherapy) 01/2018
1	Intranasal Administration 01/2003